Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18


Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease.

Unzeta M, Esteban G, Bolea I, Fogel WA, Ramsay RR, Youdim MB, Tipton KF, Marco-Contelles J.

Front Neurosci. 2016 May 25;10:205. doi: 10.3389/fnins.2016.00205. eCollection 2016. Review.


Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial.

Stallard N, Kunz CU, Todd S, Parsons N, Friede T.

Stat Med. 2015 Oct 15;34(23):3104-15. doi: 10.1002/sim.6567. Epub 2015 Jun 26.


Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors.

Leinonen A, Koponen M, Hartikainen S.

PLoS One. 2015 May 1;10(5):e0124500. doi: 10.1371/journal.pone.0124500. eCollection 2015. Review.


Estimation after subpopulation selection in adaptive seamless trials.

Kimani PK, Todd S, Stallard N.

Stat Med. 2015 Aug 15;34(18):2581-601. doi: 10.1002/sim.6506. Epub 2015 Apr 22.


The effects of galantamine treatment on attention and its relationship with cognition and activities of daily living in patients with mild to moderate Alzheimer's disease.

Lee JH, Hong YJ, Bae HJ, Kim BJ, Na DL, Han SH, Park JM, Jeong JH, Cha KR.

J Clin Neurol. 2015 Jan;11(1):66-72. doi: 10.3988/jcn.2015.11.1.66. Epub 2015 Jan 2.


The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial.

Prins ND, van der Flier WA, Knol DL, Fox NC, Brashear HR, Nye JS, Barkhof F, Scheltens P.

Alzheimers Res Ther. 2014 Jul 21;6(4):47. doi: 10.1186/alzrt275. eCollection 2014.


Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.

Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD.

J Am Geriatr Soc. 2011 Jun;59(6):1019-31. doi: 10.1111/j.1532-5415.2011.03450.x. Epub 2011 Jun 7.


Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.

Kavanagh S, Howe I, Brashear HR, Wang D, van Baelen B, Todd M, Schwalen S.

Curr Alzheimer Res. 2011 Mar;8(2):175-86.


Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.

Seltzer B.

Clin Interv Aging. 2010 Feb 2;5:1-6. Review.


Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.

Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C.

AAPS J. 2010 Jun;12(2):117-29. doi: 10.1208/s12248-009-9164-6. Epub 2010 Jan 15.


Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE.

Clin Interv Aging. 2008;3(2):211-25. Review.


Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: a 52-week prospective study.

Suh GH, Jung HY, Lee CU, Choi S; Korean Galantamine Study Group..

J Korean Med Sci. 2008 Feb;23(1):10-7. doi: 10.3346/jkms.2008.23.1.10.


A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression.

Holtzheimer PE 3rd, Meeks TW, Kelley ME, Mufti M, Young R, McWhorter K, Vito N, Chismar R, Quinn S, Dey S, Byrd EH, McDonald WM.

Int J Geriatr Psychiatry. 2008 Jun;23(6):625-31.


Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.

Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H.

BMJ. 2005 Aug 6;331(7512):321-7. Review.


Drug therapy for Alzheimer's disease.

Kavanagh S, Kabathova P.

CMAJ. 2004 Apr 27;170(9):1371-2; author reply 1372-4. No abstract available.


Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.

Rockwood K.

J Neurol Neurosurg Psychiatry. 2004 May;75(5):677-85. Review. Erratum in: J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):1086.


Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

Lanctôt KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR.

CMAJ. 2003 Sep 16;169(6):557-64. Review.

Supplemental Content

Support Center